Prognosis of generalized bullous fixed drug eruption: Comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis

British Journal of Dermatology

Volumn 168, Issue 4, 2013, Pages 726-732

  Lipowicz, S ^a   Sekula, P ^b   Ingen Housz Oro, S ^a   Liss, Y ^b   Sassolas, B ^c   Dunant, A ^d   Roujeau, J C ^a   Mockenhaupt, M ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITY OF FREIBURG   (Germany)

^c BREST UNIVERSITY HOSPITAL   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BURN UNIT; CASE CONTROL STUDY; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; FEMALE; FIXED DRUG ERUPTION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SEX DIFFERENCE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DRUG ERUPTIONS; EPIDERMAL NECROLYSIS, TOXIC; EUROPE; FEMALE; HUMANS; INFANT; LENGTH OF STAY; MALE; MIDDLE AGED; PROGNOSIS; STEVENS-JOHNSON SYNDROME; YOUNG ADULT;

EID: 84875425144     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12133     Document Type: Article

References (14)

1. Kauppinen K, Stubb S,. Fixed eruptions: causative drugs and challenge tests. Br J Dermatol 1985; 112: 575-8.
2. Baird BJ, de Villez RL,. Widespread bullous fixed drug eruption mimicking toxic epidermal necrolysis. Int J Dermatol 1988; 27: 170-4.
3. Lin T, Hsu MM, Lee JY,. Clinical resemblance of widespread bullous fixed drug eruption to Stevens-Johnson syndrome or toxic epidermal necrolysis: report of two cases. J Formos Med Assoc 2002; 101: 572-6.
4. Lyell A,. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355-6.
5. Lyell A,. Requiem for toxic epidermal necrolysis. Br J Dermatol 1990; 122: 837-8.
6. Valeyrie-Allanore L, Roujeau JC,. Epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis). In: Fitzpatrick's Dermatology in General Medicine (, Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller A, Leffell DJ, eds), 7th edn. New York: McGraw-Hill, 2007; ch. 39.
7. Mockenhaupt M,. Epidemiology and causes of severe cutaneous adverse reactions to drugs. In: Drug Hypersensitivity (, Pichler W, ed), Basel: Karger Verlag, 2007; 18-31.
8. Shiohara T,. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009; 9: 316-21.
9. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-53.
10. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study. J Invest Dermatol 2008; 128: 35-44.
11. Sekula P, Liss Y, Davidovici B, et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res 2011; 32: 237-45.
12. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6.
13. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138: 1019-24.
14. Pfütze M, Niedermeier A, Hertl M, et al. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol 2007; 17: 4-11.